Näytä suppeat kuvailutiedot

dc.contributor.authorLeino, Teppo O.
dc.contributor.authorTurku, Ainoleena
dc.contributor.authorUrvas, Lauri
dc.contributor.authorAdhikari, Karuna
dc.contributor.authorOksanen, Jouni
dc.contributor.authorSteynen, Yana
dc.contributor.authorYli-Kauhaluoma, Jari
dc.contributor.authorXhaard, Henri
dc.contributor.authorKukkonen, Jyrki P.
dc.contributor.authorWallén, Erik A. A.
dc.date.accessioned2023-05-25T06:39:26Z
dc.date.available2023-05-25T06:39:26Z
dc.date.issued2023
dc.identifier.citationLeino, T. O., Turku, A., Urvas, L., Adhikari, K., Oksanen, J., Steynen, Y., Yli-Kauhaluoma, J., Xhaard, H., Kukkonen, J. P., & Wallén, E. A.A. (2023). Azulene as a biphenyl mimetic in orexin/hypocretin receptor agonists. <i>Bioorganic and Medicinal Chemistry</i>, <i>88-89</i>, Article 117325. <a href="https://doi.org/10.1016/j.bmc.2023.117325" target="_blank">https://doi.org/10.1016/j.bmc.2023.117325</a>
dc.identifier.otherCONVID_183153867
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/87187
dc.description.abstractAzulene is a rare ring structure in drugs, and we investigated whether it could be used as a biphenyl mimetic in known orexin receptor agonist Nag 26, which is binding to both orexin receptors OX1 and OX2 with preference towards OX2. The most potent azulene-based compound was identified as an OX1 orexin receptor agonist (pEC50 = 5.79 ± 0.07, maximum response = 81 ± 8% (s.e.m. of five independent experiments) of the maximum response to orexin-A in Ca2+ elevation assay). However, the azulene ring and the biphenyl scaffold are not identical in their spatial shape and electron distribution, and their derivatives may adopt different binding modes in the binding site.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofseriesBioorganic and Medicinal Chemistry
dc.rightsCC BY 4.0
dc.subject.otheragonist
dc.subject.otherazulene
dc.subject.othermedicinal chemistry
dc.subject.otherorexin receptor
dc.subject.othersulfonamides
dc.titleAzulene as a biphenyl mimetic in orexin/hypocretin receptor agonists
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202305253251
dc.contributor.laitosKemian laitosfi
dc.contributor.laitosDepartment of Chemistryen
dc.contributor.oppiaineNanoscience Centerfi
dc.contributor.oppiaineOrgaaninen kemiafi
dc.contributor.oppiaineNanoscience Centeren
dc.contributor.oppiaineOrganic Chemistryen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn0968-0896
dc.relation.volume88-89
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 The Author(s). Published by Elsevier Ltd.
dc.rights.accesslevelopenAccessfi
dc.relation.grantnumber330800
dc.subject.ysoatsuleeni
dc.subject.ysolääkekemia
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p38581
jyx.subject.urihttp://www.yso.fi/onto/yso/p25557
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1016/j.bmc.2023.117325
dc.relation.funderResearch Council of Finlanden
dc.relation.funderSuomen Akatemiafi
jyx.fundingprogramPostdoctoral Researcher, AoFen
jyx.fundingprogramTutkijatohtori, SAfi
jyx.fundinginformationT.O.L. acknowledges the Doctoral Program in Drug Research of the University of Helsinki and the Academy of Finland (grant no. 330800); A.T. acknowledges the Finnish Cultural Foundation and the Orion Research Foundation; and J.P.K. acknowledges the Magnus Ehrnrooth Foundation, the Liv & Hälsa Foundation and Finska läkaresällskapet for financial support. Marja Peltola, Santeri Suokas and Maiju K. Rinne are acknowledged for assistance with the experiments. We would like to thank Nina Sipari from Viikki Metabolomics Unit (Helsinki Institute of Life Science, University of Helsinki; Biocenter Finland) for her expertise with the LC-MS analyses. CSC – IT Center for Science is thanked for the computational resources.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0